KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Other Operating Expenses (2016 - 2017)

Pfizer (PFE) has disclosed Other Operating Expenses for 8 consecutive years, with -$7.6 billion as the latest value for Q4 2017.

  • Quarterly Other Operating Expenses rose 2.89% to -$7.6 billion in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$7.6 billion through Sep 2018, up 67.91% year-over-year, with the annual reading at -$23.3 billion for FY2017, 3.31% up from the prior year.
  • Other Operating Expenses for Q4 2017 was -$7.6 billion at Pfizer, down from -$5.6 billion in the prior quarter.
  • The five-year high for Other Operating Expenses was $1.1 billion in Q2 2013, with the low at -$7.8 billion in Q4 2016.
  • Average Other Operating Expenses over 5 years is -$4.0 billion, with a median of -$5.2 billion recorded in 2015.
  • The sharpest move saw Other Operating Expenses skyrocketed 255.52% in 2013, then tumbled 9979.25% in 2015.
  • Over 5 years, Other Operating Expenses stood at $18.0 million in 2013, then soared by 194.44% to $53.0 million in 2014, then crashed by 14062.26% to -$7.4 billion in 2015, then dropped by 6.07% to -$7.8 billion in 2016, then grew by 2.89% to -$7.6 billion in 2017.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at -$7.6 billion, -$5.6 billion, and -$5.2 billion for Q4 2017, Q4 2017, and Q3 2017 respectively.